UPDATE: Dougherty & Company Upgrades Hologic to Buy

Dougherty & Company has published a research report on Hologic

and has upgraded the company from Neutral to Buy based on pending data from the Oslo study that recently introduced C-View software. In the report, Dougherty writes, "We believe the Oslo Study could prove to be as influential (or more) for Tomosynthesis as DMIST was for 2D Mammography. Recall, following publication of the DMIST results in the New England Journal of Medicine in September of 2005, we saw an immediate acceleration in the adoption rate for Hologic's 2D Selenias. We suspect a similar trajectory for Dimensions Tomosynthesis as we get further data points from the Oslo Study." Dougherty & Company has also raised the price target from $20 to $26 on Hologic, which is currently trading up $0.19 from yesterday's $20.73 closing price.